U.S. Imposes 100% Tariff on Imported Patent Drugs

Washington, April 3: The United States will impose tariffs of up to 100% on imported patent drugs. President Donald Trump cited national security risks and heavy reliance on foreign supply chains as the reasons behind this decision.

In the announcement, President Trump stated that drugs and their associated components are being imported into the U.S. in such quantities and under conditions that could jeopardize national security.

This new policy targets patent drugs and active pharmaceutical ingredients (APIs), which are crucial for public health services and military preparedness. The administration warned that dependence on foreign production could disrupt the availability of “life-saving drugs” during geopolitical or economic crises.

Under the order, most imported patent drugs will face a 100% ad valorem tariff. Companies that commit to relocating production to the U.S. will benefit from a reduced tariff of 20%, which will increase to 100% after four years.

The announcement also specifies different tariff rates for key trading partners. Imports from the European Union, Japan, South Korea, and Switzerland will incur a lower tariff of around 15%, while certain categories, such as orphan drugs, nuclear medicines, and gene therapies, will be exempt from these tariffs.

Currently, generic drugs and biosimilars are excluded from this tariff regime. The announcement clarified, “Generic drugs and their components… will not be subject to tariffs at this time.”

Officials indicated that this policy is part of a broader effort to strengthen domestic drug manufacturing and secure supply chains. U.S. Trade Representative Jamison Greer emphasized that the focus is not solely on tariffs but also on the long-term restructuring of production.

He noted, “The issue is not just the tariff rate but the agreements we are making with countries and companies to ensure supply chains are secure and production occurs in the U.S.”

Greer also mentioned that companies are already responding to this policy, highlighting significant progress in the construction of new pharmaceutical plants in the U.S.

These tariffs will be implemented gradually starting July 31, 2026, with some companies receiving extensions based on existing agreements.

This decision is likely to have widespread implications for the global pharmaceutical trade, particularly affecting countries that are major suppliers of finished drugs and raw materials.

India and China are among the largest producers of generic drugs and active pharmaceutical ingredients globally, supplying a significant portion of the U.S. market. While generic drugs are currently exempt, future tariff increases could have a substantial impact on global drug prices and supply chains.

The Trade Expansion Act’s Section 232 allows the U.S. President to restrict imports deemed a threat to national security. This provision was previously used to impose tariffs on steel and aluminum and is now considered a significant shift in trade policy as it extends to pharmaceuticals.

–